CoChat

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Safety Review of Adult Clinical Trial Experience with Lamotrigine

Abstract

To date approximately 4000 adults > 12 years of age have been treated with lamotrigine in Glaxo Wellcome sponsored clinical trials. Review of the data from these trials shows lamotrigine to be effective and well tolerated in both add-on and monotherapy treatment. Safety of lamotrigine was comparable to that of other anticonvulsants in add-on controlled clinical trials. In addition, fewer than half the number of patients in monotherapy studies who were taking lamotrigine discontinued treatment because of adverse events compared to those taking carbamazepine and phenytoin. Most of the reported adverse events seen in lamotrigine treated patients in all studies were judged by the investigator to be mild or moderate in severity; few of the adverse events resulted in the withdrawal of patients from studies. Analysis of vital signs and clinical laboratory data have revealed no undesirable effect of lamotrigine on major systems of the body. The most concerning adverse event has been rash. In clinical trials, this has most often been limited to a simple morbilliform rash which is not associated with evidence of systemic involvement. The incidence of Stevens-Johnson syndrome (SJS) in clinical trials is approximately 1 in 1000. Rash associated with lamotrigine has typically occurred within the first 8 weeks of treatment. Data from clinical trials clearly point to exceeding currently recommended dosage guidelines of lamotrigine and co-administration of valproic acid (valproate sodium) as risk factors for rash. Early in 1997, Glaxo Wellcome strengthened existing warnings in the product label regarding the risk of rash and reinforced the importance of adherence to administration guidelines in an effort to reduce the incidence of rash.

Overview

Integrity signals

Registry

Crossref · 10.2165/00002018-199818040-00004

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Cited by

See all 252

Metadata

Authors
Messenheimer, J., Mullens, E. L., Giorgi, L., & Young, F.
Venue
Drug Safety
Published
1998
Volume
18
Issue
4
Pages
281-296
ISSN
0114-5916 (ISSN-L)
OpenAlex
W1989801730
Cited by
252
References
27
Citations by year
2026: 2 · 2025: 3 · 2024: 4 · 2023: 4 · 2022: 6 · 2021: 6 · 2020: 6 · 2019: 33 · 2018: 5 · 2017: 3 · 2016: 6 · 2015: 4 · 2014: 7 · 2013: 6 · 2012: 8
FWCI
9.33
Type
journal article
Language
en
Open access
closed
Locations
  • Drug Safety (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
lamotrigine, adverse drug reactions, rash, Stevens-Johnson syndrome, morbilliform rash, valproic acid, dosing recommendations, carbamazepine, phenytoin, epilepsy, drug safety labeling
MeSH terms
Lamotrigine, Adolescent, Adult, Anticonvulsants, Calcium Channel Blockers, Drug Therapy, Combination, Exanthema, Female, Humans, Male, Regression Analysis, Risk Factors, Seizures, Triazines, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety Review of Adult Clinical Trial Experience with Lamotrigine. https://app.cochat.ai/papers/10.2165/00002018-199818040-00004
The paper
Messenheimer, J., Mullens, E. L., Giorgi, L., & Young, F. (1998). Safety Review of Adult Clinical Trial Experience with Lamotrigine. Drug Safety. https://doi.org/10.2165/00002018-199818040-00004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.